Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ped.12264 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lacosamide and Levetiracetam Are Not Toxic to the Developing Mouse Brain.
Ann Neurol
October 2024
Department of Neurology, University of Wisconsin, School of Medicine, Madison, WI.
Article Synopsis
- A study investigated the effects of the antiseizure drug lacosamide on neonatal mice, particularly focusing on its neurotoxic potential in combination with levetiracetam.
- * Injections of various treatments were given to the mice, including saline, phenobarbital, lacosamide, levetiracetam, and their combination.
- * Results indicated that while phenobarbital increased apoptotic cell death, neither lacosamide alone nor in combination with levetiracetam showed any significant increase in apoptosis compared to the saline group, implying they may be safer for developing brains.
Pharmacokinetic and pharmacodynamic data from the NEOLEV1 and NEOLEV2 studies.
Arch Dis Child
September 2024
Department of Pediatrics, University of California San Diego, La Jolla, California, USA.
Objectives: To confirm that levetiracetam (LEV) demonstrates predictable pharmacokinetics(PK) at higher doses and to study the pharmacodynamics(PD) of LEV.
Design: Pharmacokinetic data from the NEOLEV1 and NEOLEV2 trials were analysed using a non-linear mixed effects modelling approach. A post hoc analysis of the effect of LEV on seizure burden was conducted.
Unlocking the Therapeutic Potential: Sitagliptin's Multifaceted Approach in Drug-Resistant Epilepsy through a Novel Mechanism Inhibiting Protein Kinase C-γ and a Long-Term Potentiation Pathway.
ACS Pharmacol Transl Sci
June 2024
Department of Pharmacology, PGIMER, Chandigarh 160012, India.
Drug-resistant epilepsy is a prominent challenge in chronic neurological disorders. Valproate, commonly used to treat epilepsy, can fail due to various side effects and interactions, necessitating the exploration of alternative treatments. Our study primarily investigated sitagliptin's potential as a therapeutic agent for drug-resistant epilepsy.
View Article and Find Full Text PDFFactors influencing serum concentrations of levetiracetam in dogs with epilepsy.
J Vet Intern Med
July 2024
Département de Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada.
Background: Factors affecting serum concentrations of levetiracetam in dogs are unknown and could affect the efficacy of levetiracetam in controlling seizures in dogs with epilepsy.
Hypothesis/objectives: Higher PO doses of levetiracetam will be needed in dogs to achieve serum concentrations shown to be effective in humans. Determine factors that could influence serum levetiracetam concentrations and justify dose adjustment in some epileptic dogs.
Neonatal magnesium sulphate for neuroprotection: A systematic review and meta-analysis.
Dev Med Child Neurol
September 2024
The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria, Australia.
Aim: To review the evidence of the effects of neonatal magnesium sulphate for neuroprotection in perinatal asphyxia and hypoxic-ischaemic encephalopathy (HIE).
Method: This was a systematic review of randomized controlled trials (RCTs) (with meta-analysis) and non-RCTs assessing magnesium sulphate for treating perinatal asphyxia and HIE at 35 weeks or more gestation (primary outcomes: neonatal death and death or long-term major neurodevelopmental disability).
Results: Twenty-five RCTs (2099 infants) and four non-RCTs (871 infants) were included, 23 in low- and middle-income countries (LMICs).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!